伍俊妍;邱凯锋;曾英彤;刘韬;王若伦;魏理;王勇;郑志华;
WU Junyan;Qiu Kaifeng;ZENG Yingtong;LIU Tao;WANG Ruolun;WEI Li;WANG Yong;ZHENG Zhihua;Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University;Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences);State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center;Second Affiliated Hospital of Guangzhou Medical University;The First Affiliate Hospital of Guangzhou Medical University;Guangdong Pharmaceutical

• 1:中山大学孙逸仙纪念医院
• 2:广东省人民医院(广东省医学科学院)
• 3:中山大学肿瘤防治中心华南肿瘤学国家重点实验室肿瘤医学协同创新中心
• 4:广州医科大学附属第二医院

摘要(Abstract)：

广东省药学会2010年3月印发了我国第一个超说明书用药规范——《药品未注册用法专家共识》,提出了超说明书用药的5大原则,建立了国内公认的医疗机构超说明书用药管理标准流程;2011年发起并参与主编了我国第一本基于循证医学的超说明书用药专著——《超药品说明书用药参考》,2015年开始每年发布同样基于循证医学的《超药品说明书用药目录》;2021年5月发布《超说明书用药循证评价规范》团体标准(T/GDPA 1-2021)。有关工作成果被写入国家卫生和计划生育委员会规划教材,并在《英国医学杂志》(The BMJ)发表。2021年8月20日通过的《中华人民共和国医师法》首次将超说明书用药写入法条,与广东省药学会超说明书用药规范管理的基本原则是一致的。
In March 2010,the Guangdong Pharmaceutical Association(GDPA) issued the “Consensus on the use of medicines for unlabeled uses”,the first set of standards for off-label drug use in China, putting forward the five procedure protections that off-label drug use must meet, and then established the widely accepted standard procedure for off-label drug use management in medical institutions.In 2011,the GDPA initiated and co-edited the first book on off-label drug use based on evidence-based medicine in China, named Reference of off-label drug use.Since 2015,the GDPA issued the List of Off-label Drug Use every year, which was also based on evidence-based medicine.In May 2021,the GDPA issued the group standard The specification of evidence-based pharmaceutical evaluation method for off-label drug use(T/GDPA 1-2021).The achievement of the GDPA have been put into the clinical pharmacy textbook of the China National Health and Family Planning Commission and published in The BMJ.Now, in China, off-label drug use has for the first time been written into law, namely the new China Physicians Law, which was passed on 20 August 2021.The requirement in the law for off-label drug use is consistent with the management put forward by the GDPA.

关键词(KeyWords)： 广东省药学会;超说明书用药;医师法
Guangdong Pharmaceutical Association;off-label drug use;Physicians Law

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 伍俊妍;邱凯锋;曾英彤;刘韬;王若伦;魏理;王勇;郑志华;
WU Junyan;Qiu Kaifeng;ZENG Yingtong;LIU Tao;WANG Ruolun;WEI Li;WANG Yong;ZHENG Zhihua;Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University;Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences);State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center;Second Affiliated Hospital of Guangzhou Medical University;The First Affiliate Hospital of Guangzhou Medical University;Guangdong Pharmaceutical

Email:

DOI:

参考文献(References)：

• [1] 广东省药学会.关于印发《药品未注册用法专家共识》的通知[J].今日药学，2010,20(4):1-3. [2] Zheng Z,Xu F.Chinese pharmacists propose patient consent for unlabeled use of medications[J].J Manag Care Pharm,2010,16(8):640. [3] Fairman K A,Curtiss F R.Regulatory actions on the off-label use of prescription drugs:Ongoing controversy and contradiction in 2009 and 2010[J].J Manag Care Pharm,2010,16(8):629-639. [4] 卫生部办公厅.关于转发《北京市医疗机构处方专项点评指南(试行)》的通知[Z/OL].http://www.nhc.gov.cn/yzygj/s3590/201212/93a34b9643bc47c5acf138228c69a60e.shtml. [5] 广东省药学会.医疗机构超药品说明书用药管理专家共识[J].今日药学，2014,24(12):841-843. [6] Zheng Z,Zeng Y,Huang H.Pharmacists’ role in off-label drug use in China[J].Eur J Hosp Pharm,2018,25(2):116. [7] 张波，郑志华，李大魁.超药品说明书用药参考[M].北京：人民卫生出版社，2013. [8] 张波，郑志华，李大魁.超药品说明书用药参考[M].第2版.北京：人民卫生出版社，2019. [9] 闫素英.药学服务与沟通技能[M].北京：人民卫生出版社，2015. [10] 中国药科大学国家执业药师发展研究中心.执业药师蓝皮书-中国执业药师发展报告(2015)[M].北京：中国医药科技出版社，2016. [11] 广东省药学会内分泌代谢用药专业委员会.DPP-4抑制剂超药物说明书用法专家共识[J].今日药学，2013,23(12):777-782. [12] 伍俊妍，孙树梅.氟喹诺酮类抗菌药物在儿童应用中的专家共识[J].今日药学，2018,28(1):1-10. [13] 广东省药学会风湿免疫用药专家委员会.风湿免疫疾病(类风湿关节炎)超药品说明书用药专家共识[J].今日药学，2014,24(9):625-629. [14] 广东省药学会风湿免疫用药专家委员会.风湿免疫疾病(系统性红斑狼疮)超药品说明书用药专家共识[J].今日药学，2014,24(9):630-636. [15] 广东省药学会.风湿免疫疾病超药品说明书用药专家共识(之三):强直性脊柱炎[J].今日药学，2017,27(1):1-8. [16] 广东省药学会.广东省抗骨质疏松药物超药品说明书用法专家共识[J].今日药学，2019,29(2):73-78. [17] 陈敏英，刘紫锰.临床重症与药学超说明书用药专家共识[J].今日药学，2020,30(8):505-515. [18]广东省药学会.临床重症与药学超说明书用药专家共识(2021新增版)[J/OL].今日药学：1-22[2021-10-05].http://kns.cnki.net/kcms/detail/44.1650.r.20210924.2056.006.html. [19] 广东省药学会.超药品说明书用药目录(2021年版新增用法)[J].今日药学，2021,31(11):801-810. [20] Zheng Z,Yang M,Zeng Y,et al.Changing the perspective of off-label drug use in China[J].BMJ,2016. [21] 广东省药学会.超药品说明书用药药物经济学评价专家共识[J].今日药学，2016,26(10):681-683. [22] Zheng Z H,Yang M,Wu J Y.Ethical off-label drug-use:Need for a rethink?[J].Indian Pediatr,2017,54(6):447-450. [23] 唐蕾，任斌，符忠，等.超药品说明书用药诉讼案例分析[M].北京：人民卫生出版社，2017. [24] 广东省药学会.超药品说明书用药中患者知情同意权的保护专家共识[J].今日药学，2019,29(6):361-367. [25] 邱凯锋，何志超，陈泽鹏，等.《超说明书用药循证评价规范》团队标准解读[J].今日药学，2021,31(11):811-814. [26] 陶宏林.医师法为推进健康中国建设提供有力法律保障[N/OL].民主与法制时报，2021-08-25.http://www.npc.gov.cn/npc/c30834/202108/061f35f690f44f32a48519db3f2e4be7.shtml. [27] 郑志华，伍俊妍，陈孝.探索规范管理的“中国路径”[N].健康报，2021-09-03(5). [28] Zheng Z,Chen Z.Off-label drug use written into Chinese medical law for the first time[J/OL]International Pharmacy Journal,2021,39.www.fip.org/publications?item=393.